Circulating tumor cells and tumor derived extracellular vesicles
| Biomarker | Descriptive | Median (range)/number of patients (%) |
|---|---|---|
| CTC at T0(n = 104) | Median (range) | 0 (0–141) |
| Patients with CTC | 33 (32) | |
| Patients with CTC > 5 | 10 (10) | |
| CTC at T1(n = 63) | Median (range) | 0 (0–85) |
| Patients with CTC | 17 (27) | |
| Patients with CTC > 5 | 2 (3) | |
| Change in CTC(between T0 and T1)(n = 63) | Median (range) | 0 (− 8 − + 39) |
| Pts with decrease | 11 (16) | |
| Pts with increase | 11 (17) | |
| Pts with no change | 41 (65) | |
| tdEV at T0(n = 104) | Median (range) | 6.5 (0–1753) |
| Pts with tdEV≥18 | 27 (26) | |
| tdEV at T1(n = 63) | Median (range) | 5 (0–1975) |
| Pts with tdEV≥18 | 11 (17) | |
| Change in tdEV(between T0 and T1)(n = 63) | Median (range) | -1 (−46 − + 222) |
| Pts with decrease | 33 (52) | |
| Pts with increase | 29 (46) | |
| Pts with no change | 1 (2) |
Circulating tumor cell (CTC) and tumor derived extracellular vesicle (tdEV) count measured by CellSearch in 7.5 mL of blood aided by automated imaging. For automated imaging the Accept program was used, an open source program introduced by Zeune et al. [20–22]